© Copyright by HealthHelpZone.com. All rights reserved.
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52.5 million for the full-year 2023, and total revenue of $13.8 million for the fourth quarter of 2023.Record 137,650 AVISE® CTD tests performed for the... ❯❯❯
MARKHAM, Ontario, March 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of March 2024, representing $0.936 per Common Share on an annualized basis. The dividend will be payable on April 15, 2024 to shareholders of record as at March 29, 2024. The Company's dividends are... ❯❯❯
LifeLabs Klinrisk Score Included in KDIGO 2024 CKD GuidelineToronto, March 14, 2024 (GLOBE NEWSWIRE) -- Today, as the world marks World Kidney Day, LifeLabs, in exclusive partnership with Klinrisk, proudly announces a groundbreaking advancement in chronic kidney disease (CKD) screening and management: the inclusion of the Klinrisk Score as a validated equation in the prestigious Kidney Disease: Improving Global Outcomes (KDIGO)... ❯❯❯
Potential $150,000 in non-dilutive funding support through IPON and IP Assist ProgramsTORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, is pleased to announce it has strengthened support for its intellectual property portfolio by being a client of Intellectual Property Ontario (“IPON”) Partner Program... ❯❯❯
Dr. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, NovartisDURHAM, United Kingdom and CAMBRIDGE, United Kingdom, March 14, 2024 (GLOBE NEWSWIRE) -- S. M. Discovery Group (SMDG), a preclinical-stage company developing treatments for neurodegenerative diseases and rare pediatric disorders, announced today the appointment of Dr. Zsuzsanna Devecseri, MD, MBA, to its Board of Directors. Dr. Devecseri is a... ❯❯❯
BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on March 11, 2024, the Company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has evidenced compliance with the minimum bid price requirement set forth in... ❯❯❯
LOS ANGELES, March 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today the closing of its underwritten public offering of 5,232,500 shares of its common stock at a price to the public of $44.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 682,500... ❯❯❯
EAGLE, Idaho, March 12, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2024 Oppenheimer Healthcare MedTech & Services Conference on March 13, 2024. Lynette Walbom, Chief Financial Officer, and John Gochnour, President and Chief Operating Officer, will... ❯❯❯
LEWISVILLE, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Middlesex Recovery is proud to announce that it has earned a Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Office-Based Opioid Treatment: Addictions Pharmacotherapy (Adults) programs, located in Chelmsford, Gloucester, Norton, Stoughton, Woburn, MA and Salem, NH. This designation represents the highest level of recognitio... ❯❯❯
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. “We are pleased to welcome Khurram to the Galectin... ❯❯❯